Arcadia Biosciences Q4 EPS $(2.10) Beats $(2.58) Estimate, Sales $1.17M Miss $1.75M Estimate
Portfolio Pulse from dijoy@benzinga.com
Arcadia Biosciences reported Q4 earnings with a loss of $2.10 per share, surpassing the expected $2.58 loss, marking a 66.72% improvement from last year. However, their sales of $1.17M fell short of the $1.75M forecast, despite being a 17% increase from the previous year.
March 28, 2024 | 9:27 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Arcadia Biosciences surpassed EPS estimates but missed on sales forecasts in their Q4 report.
While Arcadia Biosciences exceeded EPS expectations, indicating operational efficiency or cost control, the miss on sales forecasts could concern investors about growth prospects. The mixed results present a neutral outlook, as the positive EPS surprise may offset concerns over missed sales targets in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100